Detection of a reactive metabolite of misonidazole in human urine.
Chemical studies have indicated that, following reduction of misonidazole to the hydroxylamine derivative, reaction with guanosine leads to the formation of a 2-carbon addition product of guanosine. In this study, the formation of the guanosine product is used to detect the presence of a reactive metabolite of misonidazole in the urine of patients treated with misonidazole. Urine samples were incubated with [14C]guanosine and the guanosine product was separated by HPLC analysis. The quantities of product vary as much as 10-fold from patient to patient and it is suggested that the assay might be useful as a predictor of patients susceptible to the development of peripheral neuropathy or other effects of misonidazole.
D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008920:Misonidazole / Q000627:therapeutic use / Q000652:urine*; D009593:Nitroimidazoles / Q000652:urine*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D008920:Misonidazole